Cargando…
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer
BACKGROUND: Peritoneal metastasis (PM) in patients with breast (BC) and endometrial cancer (EC) is rare and treatment options are limited. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) has demonstrated efficacy against PM from various cancers, but its efficacy in BC/EC patients is unknown...
Autores principales: | Rezniczek, Günther A., Giger-Pabst, Urs, Thaher, Omar, Tempfer, Clemens B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678066/ https://www.ncbi.nlm.nih.gov/pubmed/33213407 http://dx.doi.org/10.1186/s12885-020-07627-1 |
Ejemplares similares
-
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
por: Giger-Pabst, Urs, et al.
Publicado: (2018) -
Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer
por: Rezniczek, Günther A., et al.
Publicado: (2016) -
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
por: Nadiradze, Giorgi, et al.
Publicado: (2015) -
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects
por: Solaß, Wiebke, et al.
Publicado: (2013) -
Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
por: Blanco, Ana, et al.
Publicado: (2013)